Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U7ZY
|
|||
| Former ID |
DIB017007
|
|||
| Drug Name |
SP-MET-1
|
|||
| Synonyms |
S1004A receptor antagonist (cancer), Supratek; SP-MET-X1; Antimetastatic agent (oral, cancer), Supratek; S1004A receptor antagonist (oral, melanoma/breast/colorectal cancer), Supratek
Click to Show/Hide
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Preclinical | [1] | |
| Company |
Supratek Pharma Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | S100 calcium-binding protein A4 (S100A4) | Target Info | Antagonist | [2] |
| NetPath Pathway | FSH Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| TSH Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022727) | |||
| REF 2 | Lost in migration. Nat Biotechnol. 2010 Mar;28(3):214-29. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.